Research – One Stop Systems (OSS) – Initiation of Research Coverage

Posted on April 4, 2019 by Admin

Thursday, April 4, 2019

One Stop Systems (OSS)

A Leader in the High Performance Computing Space.

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Initiating Coverage. One
Stop Systems is a leader in the High Performance Computing (HPC) space with a
particular emphasis on the “AI on the Fly” and the migration to PCI
Express (PCIe) Gen 4 spaces through the design and manufacture of custom
servers, compute accelerators, solid-state storage arrays, and system expansion
systems.
A Company of
firsts. In spite of its relatively small size, OSS punches
above its weight having been the first to market with PCIe interconnect
products, the most powerful GP…

Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.

News – Stock Buybacks: Good, evil, or maybe something in between?

Posted on April 3, 2019 by Admin

Who benefits from stock repurchases, the investors or the executives?

(Note: companies that could be
impacted by the content of this article are listed at the base of the story
(desktop version). This article uses third-party references to provide a
bullish, bearish and balanced point of view; sources listed in the
“Balanced” section)

Stock buybacks are on the rise and there are concerns over the effectiveness. It is even becoming a Political issue. Share buybacks, also known as stock repurchases, are when corporations purchase its own shares in the open stock market, reducing the total number of shares outstanding. The result of the buyback could increase earnings per share and increase return on equity, possibly increasing the stock price. 2018 was an all-time, record year for buybacks, with $1.1 trillion in announcements and some $800 billion repurchased during the year. Reasons have been postulated about why the pace of buybacks has increased over the years, including the generation of significant free cash flow by companies, muted organic investment opportunities, a lack of accretive acquisitions, as a means of boosting EPS by reducing the share count. Notably, stock repurchases were illegal until 1982 and Congress is looking at curbing the exercise as a means of narrowing the growing income inequality in America and advocating an element of social responsibility. Senators Charles Schumer and Bernie Sanders penned an op-ed in the New York Times arguing that, “corporate boardrooms have become obsessed with maximizing only shareholder earnings to the detriment of workers.” The pair suggest they will introduce legislation to limit buybacks unless companies meet certain conditions, including a $15 per hour minimum wage, providing workers with decent pensions, and solid health benefits, among other things.

Research – Prize Mining (PRZ:CA) – Behind the recent deal

Posted on April 3, 2019 by Admin

Wednesday, April 3, 2019

Prize Mining (PRZ:CA)

More To The Deal Than Meets the Eye.

Prize Mining Corp is a Canada based resource exploration company. It is primarily engaged in the business activity of acquiring and exploring resource properties in Canada. All the operations of the company are carried out in Canada. The organization is focused on Kena and Daylight Gold project which is located in the Nelson area of British Columbia, Canada.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Prize announces option
agreement to acquire gold properties. Prize Mining announced a performance-based option
agreement with Denton Resources Inc., a private corporation, to acquire a 100%
interest in 62 mineral claims comprising the Carscallan property near the town
of Cochrane in northeastern Ontario, Canada. The option agreement is
contingent on approval by the TSX Venture Exchange (TSX-V).
Performance-based
payments require little up-front capital. The option agreement requires little up-front capital and
Prize has the option to move forward based on key predictors of success.
The initial capital out…

Get full report on Channelchek desktop.

Research – Aurania Resources (ARU:CA) – Updates on copper production

Posted on April 3, 2019 by Admin

Wednesday, April 3, 2019

Aurania Resources Ltd. (ARU:CA)

Scratching the Surface?

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Tsenken evolves into a high-potential copper target. High-grade copper and silver have been discovered over
a nine-kilometer trend. Recent grab samples from boulders in streams
contain up to 7% copper with 70 grams per tonne of silver. Recall that in
January, Aurania reported that grab samples of rock in streams draining from
the Tsenken-A porphyry target contained up to 9% copper with 185 grams per
tonne of silver over three kilometers.
Evidence points to a cluster of
copper porphyrys. Recent work appears to corroborate management’s earlier
belief that rather than being one very large target area, Tsenken may be a
cluster of porphyry bodies. Rather than having one potential source of
copper at Tsen…

Get full report on Channelchek desktop.

Research – Trovagene (TROV) – Updated prostate cancer data

Posted on April 2, 2019 by Admin

Wednesday, April 3, 2019

Trovagene Inc. (TROV)

Updated early prostate cancer data demonstrates sustained PSA levels.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

AACR
Presentation. The company had the second presentation from a Phase 2 study
of onvansertib in combination with Zytiga/prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC), at the American Association for
Cancer Research (AACR) annual meeting today, following the update from the
acute myeloid leukemia (AML) trial (refer to the note published on April 2nd,
2019).
Data Update in
Prostate Cancer. Onvansertib in combination with Zytiga/prednisone treatment
achieved a reduction of prostate specific antigen (PSA) levels in 2 out of
6 mCRPC patients. The previous data reported at
the Genitourinary Cancers Symposium (ASCO-GU, on February) showed
reduced PSA levels, however levels were relapsed. The company plans to
comm…

Get full report on Channelchek desktop.

Research – Trovagene (TROV) – Update on data readout

Posted on April 2, 2019 by Admin

Tuesday, April 2, 2019

Trovagene Inc. (TROV)

Improved and updated data from AML patients.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

AACR Data
Presentation. The company presented data from a Phase 1b clinical trial of
onvansertib in patients with acute myeloid leukemia (AML) at the American
Association for Cancer Research (AACR) annual meeting on April 1st, 2019. The
anti-leukemic activity improved with an increased number of patients treated.
The disease control rate (DCR) rose to 89% (17/19 patients) from previous
reported rate of 83% (10/12 patients) at The American Society of
Hematology (ASH) on December 2018.
Digging Through Data. In addition to the improved DCR, the overall response
rate also increased; one patient with complete response (CR), one
incomplete blood recovery (iCR), one morphologic leukemia-freestate (MLFS) and
one partial response (PR) compar…

Get full report on Channelchek desktop.

News – Macular Edema: The search for the cure continues

Posted on April 2, 2019 by Admin

Can any other treatment beat anti-VEGF in macular edema?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

Macular edema (ME) is an eye disease condition that causes the sudden or chronic decrease in visual acuity. The condition arises from fluid accumulation within the macula, an area in the center of the retina, leading to vascular instability and the breakdown of the blood-retinal barrier (BRB). Characterization of the diseases is made by the swelling and thickening of the macula distorting a person’s central vision, causing a decline in visual acuity and eventually could lead to blindness.

Major causes of macular edema include diabetes, branch and central retinal vein occlusion, choroidal neovascularization, posterior uveitis, postoperative inflammation and central serous chorioretinopathy.

Fluid accumulation results from an imbalance between processes governing fluid entry and exit, when inner or outer blood-retinal barriers are disrupted. ME can arise from various conditions:

7 million subjects due to diabetes, called diabetic macular edema (DME)
3 million subjects due to vein occlusion
40% of visual impairment in patients with uveitis
5% of individuals older than 60 years of age due to neovascular age-related macular degeneration (AMD) in industrialized countries

ME treatment is a rapidly growing market with an increasing elderly population, and people living with diabetes. The anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment landscape for ME providing benefit to patients, however 30-50% of patients don’t respond or develop resistance to anti-VEGF treatment and the opportunity still remains for the development of novel compounds.

Research – Albany International (AIN) – Appoints new CFO

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

Albany International Corp. (AIN)

New CFO appointment: What does it signal?

Albany International
Corp. is a textiles and materials processing company. The Company operates
through two segments: Machine Clothing (MC) and Albany Engineered Composites
(AEC). Its MC segment supplies permeable and impermeable belts used in the
manufacture of paper, paperboard, nonwovens, fiber cement and various other
industrial applications.

Christian Herbosa, Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Management
Update. After market close last Friday, AIN announced the that
its Board of Directors appointed Stephen Nolan as CFO and Treasurer, effective
today. Mr. Nolan succeeds John Cozzolino, who had served as CFO and
Treasurer since 2011.
New CFO
Background. Prior to joining AIN, Mr. Nolan served as CFO at
Esterline, where he facilitated its sale to TransDigm. He also served as CFO
for Vista Outdoor, which he helped spin-off from Alliant Techsystems (ATK). He
also worked on the merger of ATK and Orbital Sciences to create Orbital ATK.
Before those positions, Mr. Nol…

Get full report on Channelchek desktop.

Research – Sierra Metals (SMTS) – 2018 full year recap

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

Sierra Metals (SMTS)

What will drive expansion in 2019?

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Full year earnings modestly lower than expected. Sierra Metals reported a fourth quarter loss of
($0.01) per share and full year earnings of $0.12 per share, compared to our
respective per share estimates of $0.02 and $0.15. The variance to our
estimates was largely attributed to higher fourth quarter expenses, including
taxes. Fourth quarter and full year EBITDA were $15.3 million and $89.8
million.
Near-term expansions on the horizon. Production capacity at Yauricocha is expected to
increase from 3,150 tonnes per day to 3,600 tonnes per day in 2020, while
capacity at Bolivar is expected to increase from 3,600 tonnes per day to 4,200
tonnes per day by the fourth quarter of 2019. Capacity at Cusi is
expected to increase fro…

Get full report on Channelchek desktop.

Research – TherapeuticsMD (TXMD) — Assumption of Coverage

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

TherapeuticsMD (TXMD)

.

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD’s drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

…

Get full report on Channelchek desktop.

FEATURE: Research | Podcast Series | Future of Copper

Posted on April 1, 2019May 4, 2022 by Admin

Sierra Metals (SMTS) What will drive expansion in 2019? More

Albany International Corp. (AIN) New CFO appointment: What does it signal? More

The NEW podcast series, from top-trending iTunes host, Brant Pinvidic, features celebrity CEOs of iconic brands you know and love, to the emerging growth companies and entrepreneurs you should be talking about. The most innovative Ideas, the inspirational People behind them, and the wealth of Opportunities they create… that’s IPO from Channelchek. More

Salem’s radio station sell-off
reduces debt. “Michael Kupinski, director of research at Noble Capital Markets,
Inc. in Boca Raton, Fla., believes the soft first quarter guidance should not
be a trend for the company…” More

Trovagene, Inc. (TROV), a clinical-stage oncology therapeutics company news: Phase 1b/2 dose escalation trial of Onvansertib in Relapsed/Refractory AML demonstrates safety, tolerability and relative durability with complete responses at highest dose levels. More

Endeavour Silver (EXK), a mid-tier precious metals mining company that owns and operates four high-grade, underground, silver-gold mines in Mexico, achieves commercial production at El Compas mine… More

Energy Fuels (UUUU), a leading US-based uranium mining company, supplying U₃O₈ to major nuclear utilities, provides an update on Vanadium production. More

Betting on The Future of Copper. The case for Dr. Copper: new sources of demand are positive for copper. Demand for copper is poised to benefit from greater usage for electric vehicles, communications and clean energy systems, such as solar thermal plants… More